8-K: Merus Shareholders Approve Genmab Acquisition Proposals

Merus N.V. shareholders overwhelmingly approved all proposals related to the Genmab A/S acquisition, including the $97.00 per share cash offer and director appointments.

Summary

• Merus N.V. held an Extraordinary General Meeting (EGM) on December 9, 2025, to vote on proposals related to its acquisition by Genmab A/S and its wholly owned subsidiary, Genmab Holding II B.V. (Purchaser).
• The acquisition offer is for $97.00 per Common Share in cash, without interest and subject to applicable tax withholding.
• As of the record date, November 11, 2025, there were 75,847,175 Common Shares issued and outstanding and entitled to vote.
• A total of 53,764,929 Common Shares were present or represented by proxy at the EGM, representing approximately 70.88% of the outstanding shares, establishing a quorum.
• Shareholders approved Proposal 1a, which involves the Back-End Merger, a statutory merger under Dutch law where Merus N.V. will merge into Merus Merger B.V. (New TopCo), contingent on a Dutch tax ruling.
• Proposal 1b, an alternative to amend the company's articles of association, was also approved but deemed moot as the necessary Dutch tax ruling was obtained prior to the EGM.
• Proposal 2, the conditional granting of full and final discharge to each member of the company's board of directors for their acts of management or supervision, was approved.
• Shareholders approved the appointment of Greg Mueller, Anthony Pagano, and Martine van Vugt, Ph.D., as non-executive directors, effective upon the consummation of the Offer.
• Proposal 6, a non-binding advisory vote on compensation that may become payable to named executive officers in connection with the completion of the Offer, was also approved.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as shareholders have approved the acquisition, indicating a clear path forward for the transaction at the agreed-upon price, which is generally favorable for shareholders. The removal of a key contingency (Dutch tax ruling) further solidifies the deal's progression.

Positives

• Shareholders overwhelmingly approved the acquisition by Genmab A/S, indicating strong support for the $97.00 per share cash offer.
• The necessary Dutch tax ruling referenced in the Back-End Transactions proposal was obtained prior to the EGM, simplifying the post-acquisition corporate structure.
• The EGM achieved a robust quorum with approximately 70.88% of outstanding shares represented, demonstrating high shareholder engagement and clear mandate for the transaction.

Risks

• The consummation of the Offer is subject to the satisfaction or waiver of certain conditions set forth in the Transaction Agreement and the Offer to Purchase.
• The Back-End Merger is subject to certain conditions, although the Dutch tax ruling has been obtained.

Future Outlook

The tender offer is set to expire on December 11, 2025, with a subsequent offering period of at least ten business days to follow if conditions are met. Upon consummation of the offer, the company will proceed with the statutory merger and delisting of its common shares from the Nasdaq Global Market, converting into a private company with limited liability.

Industry Context

This acquisition reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger entities like Genmab seek to expand their pipelines or market presence through strategic takeovers of innovative smaller companies like Merus N.V. The cash offer indicates a clear valuation and a desire for a swift, clean transaction, aligning with trends of strategic M&A activity in the life sciences.

Management Changes

Corporate Governance

Related Party Transactions

• The Transaction Agreement, dated September 29, 2025, between Merus N.V., Genmab A/S, and Genmab Holding II B.V. for the acquisition of all issued and outstanding common shares of Merus at $97.00 per share.

Stakeholder Impact

• **Shareholders:** Will receive $97.00 per common share in cash, providing a clear and defined exit strategy and value realization for their investment.
• **Management/Executives:** Compensation may become payable to named executive officers in connection with the completion of the Offer, as approved by a non-binding advisory vote.
• **Company (Merus N.V.):** Will cease to exist as an independent publicly traded entity, becoming a part of Genmab A/S through a statutory merger.
• **Employees:** While not explicitly detailed, acquisitions typically lead to integration processes that can impact employees through organizational restructuring or changes in reporting lines.

Next Steps

• The tender offer is scheduled to expire at 5:00 p.m., New York City time, on December 11, 2025, unless extended.
• If conditions are satisfied or waived, a subsequent offering period of at least ten business days will commence after the offer expires.
• Consummation of the Offer and subsequent closing.
• Execution of the statutory merger of Merus N.V. into Merus Merger B.V. (New TopCo).
• Delisting of Merus N.V. Common Shares from the Nasdaq Global Market.
• Conversion of Merus N.V. into a private company with limited liability.

Key Dates

Recommendation

The tender offer is progressing as expected with shareholder approval, and the offer price of $97.00 per share is fixed. Investors holding shares should tender them into the offer or await the subsequent offering period, as the company is moving towards delisting and becoming a private entity. There is no further upside potential beyond the offer price, and holding shares past the offer's consummation would result in illiquidity.

Keywords

Merus N.V., Genmab A/S, Acquisition, Tender Offer, Shareholder Vote, 8-K Filing, Biotechnology, Pharmaceuticals, Merger, Corporate Governance